Trial Profile
Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib (Primary)
- Indications Mouth neoplasm; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms ERLO-XIB
- 03 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2022).
- 27 Apr 2022 Planned End Date changed from 1 Aug 2020 to 1 Apr 2023.
- 14 Jun 2019 New source identified and integrated Clinical Trials Registry - India (CTRI-2012-07-002828)